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ABSTRACT 
Improving long-term graft survival is a major challenge in kidney transplantation. Ischaemia-reperfusion 
injury is a critical early allograft insult that enhances the risk of delayed graft function, which is common 
in deceased-donor transplantation. Delayed graft function complicates the post-transplant management and 
has a negative impact on both short and long-term outcomes. The development of effective interventions 
to prevent and attenuate the injury caused by ischaemia-reperfusion is constricted by the limited ability of 
early detection of kidney damage. In recent years, clinical and translational research has focused on improve-
ments in the diagnosis of acute kidney injury and provided prognostic information that is helpful in the 
post-transplant care. Numerous biomarkers in kidney transplantation have been evaluated in the past 
decade, but, so far, evidence to support their use in routine practice is limited. The purpose of this review 
is to examine the current status of three biomarkers for early diagnosis and prognosis of delayed graft 
function, namely urinary neutrophil gelatinase-associated lipocalin, oxidative stress and cystatin C. In addi-
tion, the concept of a biomarker is addressed, as well as the existing challenges and perspectives for 
developing a biomarker. This review discusses current literature and reflects the author’s own interpretation 
and experience.
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RESUMO 
Melhorar a sobrevivência do transplante renal a longo prazo é um desafio. A lesão provocada pela 
isquemia e reperfusão constitui uma agressão precoce do enxerto renal e aumenta o risco de atraso de 
função do enxerto, que é comum no transplante de dador cadáver. A ocorrência de atraso de função do 
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INTRODUCTION 
Late failure of kidney transplants remains an 
important clinical problem and one of the leading 
causes of end-stage renal disease. Despite significant 
improvements in one-year kidney allograft survival, 
the rate of chronic graft loss after the first year 
remains significant and the actual kidney allograft 
half-life only showed a marginal improvement over 
the past decade1. The reasons for this slight improve-
ment remain unclear. It is possible that some impor-
tant determinants of long-term graft survival may not 
have changed sufficiently to improve the overall 
outcomes of kidney transplantation2. Patient death 
with a functioning allograft and chronic allograft 
failure are the two major causes of late transplant 
loss. The causes of chronic allograft failure are mul-
tifactorial and influenced by numerous immunological 
and non-immunological factors1,2. Generally, kidney 
transplants stabilize after recovering from the stress 
of implantation until declining of graft function due 
to specific diseases or conditions, such as recurrent 
renal disease, antibody-mediated rejection or a com-
mon process involving interstitial fibrosis and tubular 
atrophy the entity encompassed by the previous 
descriptive term “chronic allograft nephropathy”, and 
more recently simply ‘fibrosis/atrophy’2,3.
Improving long-term graft survival is a major chal-
lenge in kidney transplantation. A patient submitted 
to a renal transplant would wonder if his or her 
transplanted kidney will work well and how long will 
it last. When will it be possible to identify valuable 
markers to distinguish patients at increased risk of 
graft dysfunction or of losing their transplant? Can 
biomarkers signal early transplant dysfunction, a 
process that is often undetectable? Can biomarkers 
help clinicians fine-tune their prognoses?
As in every other domain in medicine, in organ 
transplantation early diagnosis and timely interven-
tion will improve outcomes. Clinicians need and 
continually look for tools to aid them on clinical 
assessment and to enhance their ability to identify 
the “vulnerable” patient at risk for graft dysfunction. 
Biomarkers are one such tool. They will allow to 
better identify high-risk individuals, to diagnose 
dysfunction promptly and accurately, and to effec-
tively prognosticate outcomes and treat patients with 
a tailored and more individualized intervention.
WHAT IS A BIOMARKER? 
Biomarker is a very broad term that can be used 
to describe any indicator of a biological state. The 
term biomarker, or biological marker, was introduced 
in 1989 as a Medical Subject Heading (MeSH) term 
and it was defined as a “measurable and quantifiable 
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enxerto condiciona a evolução do pós-transplante e tem um impacto negativo nos resultados imediatos e 
a longo prazo do transplante renal. O desenvolvimento de intervenções eficazes na prevenção e atenuação 
da lesão causada pelo processo de isquemia-reperfusão do órgão transplantado tem estado limitado pela 
ausência de marcadores precoces da lesão e disfunção renal.
Nos últimos anos, a investigação clínica e de translação tem conseguido melhorar a capacidade de 
diagnóstico da lesão aguda do enxerto renal e fornecido alguma informação de prognóstico, que pode ser 
útil no seguimento pós-transplante. Nas últimas décadas têm sido investigados inúmeros biomarcadores 
no transplante renal, mas a sua translação para a prática clínica não tem sido escassa. Esta revisão tem 
como objetivo a descrição do contexto atual de três biomarcadores para o diagnóstico precoce de atraso 
na função do enxerto: a lipocalina associada à gelatinase dos neutrófilos (NGAL), o stress oxidativo e a 
cistatina C. Adicionalmente serão abordados alguns conceitos básicos e as perpetivas de desenvolvimento 
de um biomarcador, com base numa revisão da literatura e na interpretação e experiencia pessoal de uma 
investigação em curso nessa área.
Palavras-chave: Atraso de função do enxerto, Biomarcadores, Transplante Renal
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biological parameters (eg, specific enzyme concentra-
tion, specific hormone concentration, specific gene 
phenotype distribution in a population, presence of 
biological substances), which serve as indices for 
health- and physiology-related assessments.” More 
recently, in 2001, the definition was standardized by 
the Biomarker Definitions Working Group4 as “a 
characteristic that is objectively measured and evalu-
ated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses 
to a therapeutic intervention”. In practice, biomarkers 
can improve understanding about a disease and 
provide new knowledge of pathological mechanisms, 
making possible the earlier diagnosis and the deliv-
ery of more efficacious and safer therapies. Presently, 
it is not well established how biomarkers are catego-
rized. Within the field of health care, biological mark-
ers are commonly classified based on the sequence 
of events from exposure to disease5: biomarkers of 
exposure, which are used in risk prediction, and 
biomarkers of disease, which are used in screening, 
diagnosis and prognosis.
To be clinically useful and prevent false-positive 
screening tests, a biological marker should be highly 
sensitive and specific in detecting disease or any 
other outcome. Regardless of the purpose for its 
use, it should be accurate, reproducible and stan-
dardized across different clinical units. Furthermore, 
it should be easily measured in a standard biological 
source (as blood or urine), obtained from a person 
(as blood pressure or electrocardiogram), or image-
based (echocardiogram or computerized tomography 
scan), so that the information would be readily avail-
able and easy to interpret by clinicians5,6. In sum-
mary and according to the Food and Drug Adminis-
tration, an ideal biomarker should be specific, 
sensitive, predictive, robust, simple, accurate, and 
inexpensive.
 BIOMARKERS IN KIDNEY  
TRANSPLANTATION
In organ transplantation, initial graft dysfunction is 
one of the most important early post-operative prob-
lems, mainly due to the unavoidable ischemia-reper-
fusion injury that occurs in the transplanted organ. In 
kidney transplantation, ischemic injury of the renal 
allograft is a critical early insult that augments the risk 
of acute tubular necrosis and long-term graft loss7,8. 
The development of effective interventions is con-
stricted by the limited ability of early detection of graft 
dysfunction. Current clinical indicators of kidney injury, 
like serum creatinine, are inadequate for timely diag-
nosis and prognosis. Thus, application of biomarkers 
in the field of kidney transplantation will allow to 
detect incipient graft dysfunction or rejection, will refine 
diagnoses and enable more effective post-transplant 
management, and thereby potentially improve short-
term (e.g., delayed graft function, acute rejection) and 
long-term (e.g., allograft failure) outcomes.
Discovery of biomarkers is expanding at an unprec-
edented rate. Numerous biomarkers in kidney trans-
plantation have been evaluated in the past decade, 
but, so far, evidence to support their use in routine 
practice is limited. In this article, we review the 
promising role of three biomarkers of delayed graft 
dysfunction, namely, neutrophil gelatinase-associated 
lipocalin, oxidative stress, and cystatin C.
 NEUTROPHIL GELATINASE- 
ASSOCIATED LIPOCALIN
Neutrophil gelatinase-associated lipocalin (NGAL) 
is one the most promising biomarkers of acute kid-
ney injury in a variety of acute clinical settings9-11. 
Neutrophil gelatinase-associated lipocalin, also 
known as human neutrophil lipocalin or lipocalin-2, 
is a 25-kDa glycoprotein belonging to the lipocalin 
family and originally it was found covalently bound-
ed to gelatinase in activated neutrophils. This lipoc-
alin behaves as a bacteriostatic agent in acute 
infections and it is released to blood from activated 
neutrophils during inflammatory processes. It was 
demonstrated that NGAL exists in two separate body 
pools, the systemic and the renal one. In the sys-
temic pool, NGAL is normally expressed at very low 
concentrations in several human tissues. After glom-
erular filtration, circulating NGAL is reabsorbed in 
the proximal tubules, catabolized and finally released 
with urine in small quantities. In the renal pool, 
NGAL is rapidly released from renal tubular cells in 
response to various insults to the kidney. Thus, in 
steady situations, NGAL is found in urine only in 
trace. In contrast, when massive NGAL quantities are 
expressed and excreted in urine this usually indicates 
injury and damage of proximal tubular cells, due to 
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ischaemia-reperfusion injury, hypoxia, nephrotoxins 
or chronic progressive changes12,13.
Ischaemia-reperfusion injury is an inevitable con-
sequence of kidney transplantation procedure and 
can be considered a form of post-transplantation 
acute kidney injury. For this reason, several studies 
investigated the utility of NGAL for the diagnostic 
and prognostic of acute graft dysfunction following 
kidney transplantation, with promising results14-19. 
Recently, the prognostic value of NGAL on graft 
function at one year post-transplantation was also 
examined18,20.
The larger study on this subject is from Hollmen 
and colleagues18. These researchers demonstrated 
that urinary NGAL (uNGAL) is an early predictor of 
delayed graft function (DGF) following renal trans-
plantation, in a prospective cohort study of 176 adult 
recipients transplanted with deceased-donor kid-
neys. Urine was collected before transplant, at then 
at days 1, 3, 7 and 14, and NGAL was measured at 
each time point. The uNGAL measured in the first 
morning following transplantation predicted DGF 
(defined as the need for dialysis during the first 
week after transplantation), particularly in cases 
where early graft function was expected on the basis 
of diuresis and decreasing plasma creatinine con-
centration. Patients who needed dialysis in the first 
post-transplant week had a slower decrease in 
uNGAL compared with recipients without DGF, and 
levels of uNGAL at day-1 predicted DGF (area under 
the curve (AUC) of 0.75). In 15 of 112 cases with 
urine output higher than 1L at day-1, uNGAL was a 
predictor of DGF, as well in 19 of 86 cases with a 
day-1 decrease in creatinine over than 1 mg/dl (AUC 
0.74). Other authors showed also prominent results. 
Parikh et al. in a prospective study that included 53 
consecutive patients undergoing living or deceased-
donor transplantation (children and adults), mea-
sured NGAL in urine samples collected within the 
first 24 hours after transplantation and reported an 
AUC-ROC of 0.9 in predicting DGF14. Hall and cowork-
ers evaluated uNGAL within 6h after transplantation 
in a 91-patient cohort of adults with a kidney graft 
from a deceased-donor, and predicted subsequent 
DGF with an AUC-ROC of 0.8116.
Across a range of clinical studies, both urine and 
plasma NGAL has been shown to be a useful dis-
criminatory marker of renal injury and an early 
predictor of DGF, with a performance greater than 
serum creatinine, the most commonly used surrogate 
measurement of glomerular filtration rate. In our 
experience, and similarly to other authors14,18, we 
have chosen to measure NGAL in urine (uNGAL), 
instead of blood, since uNGAL represents tubule 
damage in the kidney rather than filtration from 
blood13,21. Although plasma NGAL is freely filtered 
by the glomerulus, it is largely reabsorbed in proxi-
mal tubules by efficient megalin-dependent endocy-
tosis11. Thus, any urinary excretion of NGAL is likely 
only when there is concomitant proximal renal tubu-
lar injury that precludes NGAL reabsorption and/or 
increases de novo NGAL synthesis. Accordingly, an 
increased level of NGAL in urine usually indicates 
injury and damage of tubular cells and seems to be 
more specific compared to serum NGAL, which can 
be produced by other organs and released into the 
circulation following a transplant surgery21. The non-
invasive nature of sample collection and the reduced 
number of interfering proteins were also other 
advantages taken in account when we choose to 
measure this biomarker in urine10.
However, despite the undoubtedly value of uri-
nary markers of kidney injury, their use in transplant 
recipients can be also a drawback because of pos-
sible transient graft anuria, which may preclude the 
availability of urine and consequently the lack of 
sample to measure NGAL. The persistent urine pro-
duction by the native kidneys and the usual fluctua-
tions of hydration status in these patients can also 
induce potential changes in urinary biomarker con-
centration, which can be another inconvenience to 
measure NGAL in urine. The genesis and sources of 
plasma and urinary NGAL require further clarification. 
However, despite the uncertainty of whether NGAL 
level performs better in urine or plasma/serum, both 
plasma/serum and urine NGAL levels appear to per-
form similarly well and provide a relevant advantage 
compared with serum creatinine, which is an insen-
sible marker of kidney injury9.
OXIDATIVE STRESS 
Oxidative stress is one of the most important 
components of the ischaemia-reperfusion process22-24. 
It reflects an imbalance between reactive oxygen spe-
cies (ROS) and cellular mechanisms for detoxifying 
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the reactive intermediates or for repairing the result-
ing damage. Disturbances in the normal state can 
cause toxic effects through the production of perox-
ides and free radicals that damage all components of 
the cell.
Oxygen free radicals or, more generally, ROS are 
products of normal cellular metabolism. It has been 
estimated that the average person has around 10,000–
20,000 free radicals attacking each body cell every day. 
Free radicals are defined as molecules or molecular 
fragments containing one or more unpaired electrons 
in atomic or molecular orbitals, which gives a consider-
able reactivity to the free radical. The well-known radi-
cals derived from oxygen, such as superoxide (O2−·), 
hydrogen peroxide (H2O2) and the hydroxyl radical 
(OH·) represent the most important class of radical 
species generated in living systems25.
In physiological conditions, ROS are produced 
specifically to serve essential biological functions, 
as in defence against infections. In these conditions, 
the rates of free radical production and elimination 
are equal, leading to a steady state that is presum-
ably tolerated by the cell. The antioxidant defence 
mechanisms can be divided into two major groups: 
endogenous, mainly enzymes, such as superoxide 
dismutases (SOD), catalases, glutathione reductases 
(GR) and peroxidases (GPx) and small molecules, 
mostly exogenous, acting as free radical scavengers 
(vitamins A, C, and E, carotenoids and polyphenol)25. 
In some pathological conditions, an imbalance 
between ROS generation and antioxidant capacity 
leads to enhanced ROS activity and oxidative stress. 
When these antioxidant mechanisms cannot coun-
terbalance the amount of free radicals generated, 
cell damage and tissue injury can take place26.
Reactive oxygen species may cause tissue injury 
via several mechanisms. As they are potent oxidizing 
and reducing agents, ROS directly damage cellular 
membranes and modify several biological molecules, 
such as lipids, proteins, and nucleic acids. The by-
products of these reactions can serve as biomarkers 
of oxidative stress22,23. Of the many biological targets 
of oxidative stress, lipids are the most involved class 
of biomolecules. Lipid oxidation generates a huge 
variety of secondary products, including reactive car-
bonyl compounds, such as malondialdehyde (MDA). 
This aldehyde is the principal and most studied prod-
uct of polyunsaturated fatty acid peroxidation, and 
for this reason MDA is a marker widely used to assess 
lipid peroxidation25,26.
Markers of oxidative stress, including elevated 
levels of MDA and reduced antioxidant activity have 
been reported in renal patients27,28. There is huge 
amount of literature concerning oxidative stress and 
renal disease but data about kidney transplantation 
in the early stages are scarce. The restoration of 
kidney function after transplantation can lead to 
improvement of the oxidative stress29, but some 
studies report increased systemic biomarkers of 
oxidative stress in kidney transplant recipients30,31, 
specifically in the early phase of transplantation32,33 
and, thereafter, coexisting with chronic allograft 
tubular atrophy/interstitial fibrosis30,34.
It has long been suspected that oxidative stress 
contributes to injury of ischaemic and reperfused 
tissues. In the setting of kidney transplantation, not 
only are there ischaemic and reperfusion periods 
obligated by the preservation and implantation 
procedures, but placement of the kidney into an 
immune milieu can also act as an adjuvant for oxida-
tive damage. Reactive oxygen species are generated 
during both phases of ischaemia-reperfusion. As in 
other clinical conditions, if the scavenging capacity 
of kidney is beneath the excessive ROS generated, 
such oxidative imbalance may trigger a robust 
inflammatory response within the transplanted organ 
and lead to cellular destruction, tissue damage and 
graft dysfunction33,35. Thus, severe reperfusion injury 
is a risk factor for DGF and detection of ROS could 
be an early warning of graft injury. Waller and 
coworkers studied blood samples in porcine kidney 
allografts before and after reperfusion injury and 
demonstrated that both plasma carbonyl and 8-ispo-
rostane (product of protein and lipid damage by free 
radicals respectively) could be reliable biomarkers 
to predict the reperfusion injury36. To the author’s 
knowledge, no similar studies were done on this 
topic in human kidney transplantation.
A wide range of antioxidant enzymes may poten-
tially exert a protective influence by limiting the 
production of ROS and the damage of oxidative stress 
following ischaemia-reperfusion injury of kidney graft. 
Conflicting results are reported in the literature on 
the activities of antioxidant enzymes in kidney trans-
plant patients. Glutathione compounds and SOD have 
been reported to increase37,38 decrease31 or not 
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change39 following renal transplantation. Whitin et 
al.37 reported a rapid increase in plasma GPx activity 
after transplantation. The plasma GPx activity was 
two times higher 3 days after transplantation in adult 
patients who received a kidney transplant from a 
related donor; and rapidly increased over the first 2 
weeks post-transplant in adult recipients from a 
deceased-donor and paediatric patients undergoing 
kidney transplantation from related donors. Zachara 
et al.38 have shown that plasma GPx activity increased 
rapidly 3 days after renal transplantation, and dou-
bled two weeks later. Both of these studies suggested 
that monitoring plasma GPx might be a useful marker 
for monitoring transplanted kidney function and a 
valuable tool for post-operative detection of DGF.
Not only in the early post-transplant period but 
also at longer-term, oxidants and antioxidants can 
be as biomarkers of graft dysfunction with diagnostic 
accuracy. Oxidative stress is believed to be a com-
mon pathway that leads to both immunological and 
non-immunological stress in the setting of kidney 
transplantation and to the development or progres-
sion of chronic allograft nephropathy. Increased 
plasma and intragraft levels of MDA and reduced 
antioxidant activity were found in kidney allografts 
with chronic tubular atrophy/interstitial fibrosis, 
which suggests the possibility of early detection, 
even when graft dysfunction is undetectable by 
serum creatinine30,34,40.
The understanding about oxidative stress signifi-
cantly advanced in the last decade, but these experi-
mentally derived ideas have yet to be fully integrated 
into clinical practice. General evidence for involve-
ment of ROS in hypoxia-reoxygenation injury includes 
detection of lipid peroxidation. Malondialdehyde is 
an end-product of lipid peroxidation and it is a 
frequently measured biomarker of oxidative stress. 
Studies on this topic are limited in kidney transplan-
tation. Therefore, more research is needed to clearly 
define the role and clinical value of MDA and other 
oxidative stress markers in kidney transplantation.
CYSTATIN C 
Cystatin C (CysC) is a low molecular mass protein 
that is produced at a constant rate by nearly all-
human nucleated cells. This cystatin is freely filtered 
through the normal glomerular membrane, almost 
completely reabsorbed and degraded by proximal 
tubular cells, but it is not secreted by the tubules. 
Although its clearance cannot be measured because 
of this catabolism, its plasma or serum concentration 
has been shown to be independent of muscular 
mass, inflammatory diseases, sex, age or diet, and 
these properties make it a good measure of glom-
erular filtration rate (GFR) compared to the tradi-
tional measurement of creatinine41,42. As a result of 
this finding, several prediction equations have been 
derived from both paediatric and adult patients to 
estimate GFR from the serum CysC concentra-
tion43,44. Most of the studies that compared CysC 
levels or CysC derived equations with gold standard 
methods found CystC to be superior or, at least, 
equivalent to serum creatinine42. Some studies on 
selected patient groups, whose muscle mass is either 
reduced or undergoes rapid changes, also demon-
strated CysC as a sensitive marker of GFR and 
independently of body composition41.
Renal transplant recipients are a target group for 
whom precise determination of GFR is crucial. 
Allograft function following renal transplantation is 
commonly monitored using serum creatinine. How-
ever, plasma creatinine is far from being an ideal 
marker of GFR, despite its convenience and low 
cost. Since the first publication in 199845, quite a 
few original clinical papers have addressed the 
question of the use of CysC in kidney transplanta-
tion. A good number of studies identified serum 
CysC (or CysC-based equations) as a promising, 
easily measurable marker to estimate GFR with a 
higher diagnostic value than serum creatinine (or 
creatinine-based equations) and 24-hour creatinine 
clearance for evaluation of GFR in the follow-up of 
adult kidney transplant patients46-48. Very recently, 
Masson et al.48 validated both of CysC-based CKD-
EPI equations (2012) in 670 kidney transplant 
recipients and concluded that both performed better 
than the serum creatinine-based CKD-EPI equation 
(2009).
Glucocorticoid medication can be shortcoming in 
using serum CysC in this population and it is impor-
tant to take into account when interpreting this 
serum marker. Glucocorticoid therapy is one of the 
few circumstances identified that have an impact on 
the production of CysC in a dose-dependent manner, 
leading to systematic underestimation of GFR49. Very 
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large doses of glucocorticoids have been described 
to increase the production of CysC49, whereas low 
and medium doses of glucocorticoids do not seem 
to alter the production of CysC50. This, however, 
does not preclude the use of CysC in detecting 
impaired renal function in renal transplant patients 
on glucocorticoids, given that many studies have 
shown CysC to be still significantly more accurate in 
detecting impaired renal function in this patient 
group49,50.
For kidney recipient follow-up, the ability to detect 
rapid changes in GFR is clinically more important 
than accuracy itself. For this reason, and due to the 
promising findings of CysC in kidney transplantation, 
the role of this marker in detecting post-transplant 
renal damage earlier than serum creatinine has been 
investigated51-54. Thervet et al.51 in a prospective 
study of 30 renal transplant patients found that CysC 
allowed earlier diagnosis of renal function recovery 
than serum creatinine, particularly in patients with 
DGF. In a prospective study that included 30 con-
secutive patients with end-stage renal disease 
undergoing renal transplantation, Le Bricon et al. 
evaluated CysC as a marker of allograft function 
during the early post-operative transplantation 
period. Serum CysC was more sensitive than serum 
creatinine for detecting decreases in GFR and predict-
ing DGF. Furthermore, a more prominent rise in 
plasma CycC values allowed a more rapid diagnosis 
of acute rejection or treatment nephrotoxicity, with 
the potential for more timely intervention52. Hall et 
al. also confirmed these findings in a cohort of 78 
deceased-donor renal recipients and shown that 
CysC outperformed serum creatinine as a predictor 
of poor early graft function and the need for dialysis 
within the first week of kidney transplantation. The 
authors also proved that CysC was a good prognostic 
marker of graft function at 3 months53. In a recent 
article published in June 2012, Liu et al. evaluated 
the clinical value of CysC for the diagnosis of an 
acute rejection episode after renal transplantation 
in 76 recipients and concluded that CysC can predict 
acute rejection episode after renal transplantation55. 
Urine CysC was also studied recently by Hall et al.54 
in a prospective multicenter study that included 91 
deceased-donor kidneys transplants. Serial urine 
samples were collected for 2 days following trans-
plant and on the first post-operative day urine CysC 
was a predictor of DGF and of 3-month allograft 
function.
Cystatin C displays several good characteristics 
that make it a viable biomarker for early detection 
of DGF. Of the three markers addressed in this 
review, serum CysC is probably the biomarker most 
used and closest to the clinical validation in kidney 
transplantation.
THE AUTHOR’S EXPERIENCE 
The Renal Transplant Unit at the Centro Hospitalar 
do Porto conducted a prospective, longitudinal study 
in 40 consecutive end-stage renal disease patients 
undergoing living or deceased-donor kidney trans-
plantation, from December 2010 to May 2011. This 
study aimed to identify early markers of graft dys-
function in the peritransplant period and investigate 
their accuracy in predicting DGF (defined as dialysis 
requirement within the first week after transplanta-
tion). The receiver operating characteristic curve 
analysis is commonly used to evaluate biomarker 
utility in clinical diagnosis of disease, especially dur-
ing biomarker development research. Using this 
statistical tool, the present study demonstrated 
uNGAL, MDA and CysC as good diagnostic markers 
on identifying patients with graft dysfunction in the 
early post-transplant period and who required dialy-
sis in the first week (articles submitted or in draft). 
When analyzed separately, all three biomarkers pre-
dicted who would develop DGF with about the same 
degree of accuracy, and all of them with a diagnostic 
performance superior to serum creatinine.
Despite these encouraging results, this is not 
enough to certify any of these markers as diagnostic 
and prognostic biomarkers with wide clinical utility. 
Before each of these (or any other) biomarkers can 
be deployed in the clinic, they have to be repeatedly 
tested in hundreds of patients to assure that they 
serve as effective markers of acute graft dysfunction 
and prognostic indicators of dialysis-based DGF. It 
is a long and laborious pathway from identifying to 
validating a reliable biomarker.
Delayed graft function is a common complication 
affecting renal grafts immediately after transplanta-
tion. Since DGF has so many detrimental effects, 
accurate and early identification of features of DGF 
is remarkably important because it would allow more 
targeted and personalised treatment approaches. 
Biomarkers in Kidney Transplantation: Translating to clinical practice
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Several studies were done in renal transplantation 
to identify biomarkers for the diagnosis of DGF. 
However, there is still no routine application of any 
of these markers in clinical transplantation. The first 
step was taken in the long march to translate a 
biomarker from the laboratory into the clinical prac-
tice. Generation of prospective data will now be 
necessary for validation and demonstration of the 
clinical utility of these markers in other centres and 
transplant recipients, across different practices and 
sets of variables. If validated, these biomarkers will 
be a major advantage for transplant recipients by 
allowing their care team to detect acute kidney injury 
before the risk of graft dysfunction becomes too 
high and the possibility of intervention less 
effective.
CONCLUSIONS 
In renal transplant patients, early detection of 
impaired kidney function is critical so that efforts to 
prevent further deterioration of graft function or 
rejection can be instituted. Biomarker investigations 
are now an integral part of clinical research. The 
overall expectation of a biomarker is to enhance the 
ability to detect earlier an ongoing biological process 
and predict which patients will respond better to 
which interventions. To bring biomarkers to the 
clinic, it is mandatory to show a useful clinical appli-
cation that is supported by the validation data. In 
the field of kidney transplantation, some biomarkers 
have successively gone the process of discovery and 
of validation, but fall short in their ability to con-
tribute decisively to patient care. In a time of greater 
economic constraints and more personalized medi-
cine, biomarkers are certain to have a presence in 
transplant care and coordinated and collaborative 
efforts should be made to implement novel biomark-
ers into the clinical practice.
Conflict of interest: None declared.
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